Yazar "Karahacioglu, Eray" seçeneğine göre listele
Listeleniyor 1 - 2 / 2
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Adjuvant radiotherapy for Stage I seminoma: A Single-institutional experience(Wolters Kluwer Medknow Publications, 2019) Kanyilmaz, Gul; Saricanbaz, Irem; Bora, Huseyin; Karahacioglu, Eray; Erkal, Eda YirmibesogluObjectives: There is no consensus regarding the management of Stage 1 seminomas following inguinal orchiectomy. In this study, we evaluated the treatment results and treatment-related toxicity for patients with Stage 1 seminomas treated with adjuvant radiotherapy (RT) at a single institution. Methods: Sixty-five patients who underwent adjuvant RT following orchiectomy for Stage 1 seminomas between January 1996 and December 2007 were retrospectively reviewed. The age, tumor location, histopathological type, stage, tumor size, RT field, and radiation dose were recorded for all patients. Results: The patients' ages ranged from 17 to 61 years (median, 37 years). Sixty-three patients (97%) were diagnosed with classical seminoma and the remaining two patients (3%) had spermatocytic seminoma. After orchiectomy, 37 patients (57%) received para-aortic RT and 28 patients (43%) received dog-leg field RT. RT was applied with 1.8u2 Gy/day fractionation and the median RT dose was 26 Gy (range, 20u38). Follow-up ranged from 0.3 to 18 years (median, 9.5 years). Local control had been achieved in all patients and all of them were alive with no evidence of disease. Fifty-one patients (77%) had at least 5 years of follow-up and 27 patients (41%) had at least 10 years of follow-up. Overall survival at 10 years was 100%. Conclusion: Although retrospective in nature, this single-institutional study provides useful information about the outcomes and toxicities associated with adjuvant RT in patients with Stage 1 seminomas reporting excellent disease control and survival rates at the expense of acceptable toxicity.Öğe Prognostic Importance of Ki-67 Labeling Index in Grade II Glial Tumors(Kare Publ, 2018) Kanyilmaz, Gul; Onder, Hatice; Aktan, Meryem; Koc, Mehmet; Bora, Huseyin; Karahacioglu, Eray; Erkal, Haldun SukruOBJECTIVE To date, several methods have been identified for predicting the prognostic subgroups of grade II gliomas; however, these methods have some limitations in predicting survival. So, we aimed to determine the predictive role of Ki-67 labeling, index (LI) on survival. METHODS Between 1995 and 2011, patients with grade II, gliomas were retrospectively analyzed. All patients received radiotherapy (RT). RESULTS This study included 78 patients with median 44 (range, 6-137) months follow-up. Patients aged >= 40 years had a poorer overall survival (OS) than those aged <10 years (p=0.04). Patients with gross total resection/ subtotal resection had a longer OS than those with biopsy/partial resection (p=0.001). If the disease had recurrence or progression during the follow-up period, the patients had a poorer OS (p=0.01). Patients with a Ki-67 LI >= 4% had a poorer OS than those with Ki-67 LI < 4%(p=0.001). The extent of resection, recurrence, or progression, and Ki-67 LI >= 4% were the independent prognostic factors for OS. CONCLUSION In our opinion, Ki-67 LI is an important prognostic factor for grade II gliomas, hut it cannot be used as a diagnostic measure alone. It must be used in combination with the other prognostic factors.